INSURE: a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practice.
Xavier LeleuHans C LeeJeffrey A ZonderMargaret MacroKarthik RamasamyCyrille HulinJiri SilarMatyas KuhnKaili RenNawal Bent-EnnakhilDasha CherepanovDawn Marie StullEvangelos TerposPublished in: Future oncology (London, England) (2024)
Aim: We pooled data from three observational studies (INSIGHT MM, UVEA-IXA and REMIX) to investigate the real-world effectiveness of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory myeloma. Materials & methods: INSIGHT MM was a prospective study conducted in countries across Europe, Asia and North/Latin America while UVEA-IXA and REMIX were multicenter, retrospective/prospective studies conducted in Europe. Patients who had received IRd as ≥2nd line of therapy were analyzed. Primary outcomes were time-to-next treatment (TTNT) and progression-free survival (PFS). Results: Overall, 564 patients were included (median follow-up: 18.5 months). Median TTNT and PFS were 18.4 and 19.9 months; both outcomes were numerically longer for earlier versus later lines. Median treatment duration was 14.0 months. Overall response rate was 64.6%. No new safety concerns were noted. Conclusion: The effectiveness of IRd in routine practice appears similar to the efficacy observed in TOURMALINE-MM1. IRd benefit in earlier versus later lines was consistent with previous reports.
Keyphrases
- multiple myeloma
- newly diagnosed
- free survival
- randomized controlled trial
- primary care
- systematic review
- acute lymphoblastic leukemia
- acute myeloid leukemia
- healthcare
- low dose
- diffuse large b cell lymphoma
- high dose
- ejection fraction
- end stage renal disease
- cross sectional
- clinical practice
- stem cell transplantation
- prognostic factors
- type diabetes
- electronic health record
- machine learning
- stem cells
- skeletal muscle
- big data
- cell therapy
- adverse drug
- deep learning
- quality improvement